Aurobindo Pharma Limited (AUROPHARMA.BO)
INR 1264.95
(1.37%)
INR 1264.95
(1.37%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 24.64 Billion | 23.86 Billion | 50.16 Billion | 33.29 Billion | 43.81 Billion | 16.5 Billion |
| Net Income | 31.72 Billion | 26.12 Billion | 33.72 Billion | 73.43 Billion | 37.43 Billion | 30.91 Billion |
| Depreciation & Amortization | 15.21 Billion | 12.44 Billion | 11.26 Billion | 10.55 Billion | 9.66 Billion | 6.67 Billion |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -16.75 Billion | -10.94 Billion | 15.57 Billion | -10.66 Billion | 3.07 Billion | -14.84 Billion |
| Other non-cash items | 34.73 Billion | -3.75 Billion | -10.4 Billion | -40.03 Billion | -6.36 Billion | -6.23 Billion |
| Investing Cash Flow | -45.36 Billion | -39.77 Billion | -32.11 Billion | 5.98 Billion | -15.67 Billion | -29.02 Billion |
| Investments in PPE | -35.61 Billion | -27.2 Billion | -27.04 Billion | -18.73 Billion | -14.31 Billion | -15.59 Billion |
| Acquisitions | 602.8 Million | -915.9 Million | -6.24 Billion | 27.46 Billion | -1.68 Billion | -13.66 Billion |
| Investment purchases | -257 Million | -20.14 Billion | -8.24 Billion | -3.13 Billion | -1.87 Billion | -463.1 Million |
| Sales/Maturities of investments | 1.79 Billion | 23.51 Billion | 4.61 Billion | -3.68 Billion | 1.8 Billion | -386.3 Million |
| Other Investing Activities | -11.89 Billion | -15.03 Billion | 4.81 Billion | 4.08 Billion | 397.6 Million | 1.07 Billion |
| Financing Cash Flow | 10.51 Billion | 18.14 Billion | -29.69 Billion | -13.64 Billion | -19.47 Billion | 19.19 Billion |
| Debt repayment | -14.61 Billion | -56.5 Million | -25.53 Billion | -11.35 Billion | -15.29 Billion | -3.93 Billion |
| Dividends payments | -2.63 Billion | -4.39 Billion | -2.63 Billion | -2.34 Billion | -1.88 Billion | -1.59 Billion |
| Common Stock Repurchased | - | - | - | - | -2.29 Billion | 24.72 Billion |
| Common Stock Issuance | - | - | - | - | 1.9 Million | 600 Thousand |
| Other Financing Activities | -3.97 Billion | 22.59 Billion | -1.51 Billion | 53.1 Million | -127.9 Million | -138.6 Million |
| Accounts receivables | -2.64 Billion | -4.31 Billion | -4.08 Billion | 7.11 Billion | -6.58 Billion | -202.4 Million |
| Accounts payables | 5.82 Billion | 7.07 Billion | 1.1 Billion | 1.26 Billion | 2.95 Billion | -3.74 Billion |
| Inventory | -13.03 Billion | -9.26 Billion | 14.97 Billion | -16.21 Billion | -5.26 Billion | -8.86 Billion |
| Other working capital | -6.9 Billion | -4.44 Billion | 3.57 Billion | -2.83 Billion | 11.97 Billion | -2.03 Billion |
| Cash at beginning of period | 43.98 Billion | 41.62 Billion | 53.29 Billion | 27.46 Billion | 18.75 Billion | 12.09 Billion |
| Cash at end of period | 62.78 Billion | 43.92 Billion | 41.62 Billion | 53.29 Billion | 27.46 Billion | 18.75 Billion |
| Capital Expenditure | -35.61 Billion | -27.2 Billion | -27.04 Billion | -18.73 Billion | -14.31 Billion | -15.59 Billion |
| Effect of forex changes on cash | 141.7 Million | -600 Thousand | 2 Million | -21.2 Million | 47.8 Million | -18 Million |
| Net cash flow / Change in cash | 18.79 Billion | 2.29 Billion | -11.67 Billion | 25.83 Billion | 8.71 Billion | 6.65 Billion |
| Free Cash Flow | -10.96 Billion | -3.33 Billion | 23.11 Billion | 14.55 Billion | 29.5 Billion | 918.7 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 31.72 Billion | 9.36 Billion | 7.57 Billion | 5.7 Billion | 26.12 Billion | 5.06 Billion |
| Depreciation & Amortization | 15.21 Billion | 4.23 Billion | 4.17 Billion | 3.26 Billion | 12.44 Billion | 3.45 Billion |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -16.75 Billion | - | - | - | -10.94 Billion | - |
| Other non-cash items | 34.73 Billion | -4.23 Billion | -4.17 Billion | -3.26 Billion | -3.75 Billion | -3.45 Billion |
| Investing Cash Flow | -45.36 Billion | - | - | - | -39.77 Billion | - |
| Investments in PPE | -35.61 Billion | - | - | - | -27.2 Billion | - |
| Acquisitions | 602.8 Million | - | - | - | -915.9 Million | - |
| Investment purchases | -257 Million | - | - | - | -20.14 Billion | - |
| Sales/Maturities of investments | 1.79 Billion | - | - | - | 23.51 Billion | - |
| Other Investing Activities | -11.89 Billion | - | - | - | -15.03 Billion | - |
| Financing Cash Flow | 10.51 Billion | - | - | - | 18.14 Billion | - |
| Debt repayment | -14.61 Billion | - | - | - | -56.5 Million | - |
| Dividends payments | -2.63 Billion | - | - | - | -4.39 Billion | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | 22.59 Billion | - |
| Accounts receivables | -2.64 Billion | - | - | - | -4.31 Billion | - |
| Accounts payables | 5.82 Billion | - | - | - | 7.07 Billion | - |
| Inventory | -13.03 Billion | - | - | - | -9.26 Billion | - |
| Other working capital | -6.9 Billion | - | - | - | -4.44 Billion | - |
| Cash at beginning of period | 43.98 Billion | 70.71 Billion | 63.14 Billion | 43.98 Billion | 41.62 Billion | 38.92 Billion |
| Cash at end of period | 62.78 Billion | 9.36 Billion | 70.71 Billion | 5.7 Billion | 43.92 Billion | 43.98 Billion |
| Capital Expenditure | -35.61 Billion | - | - | - | -27.2 Billion | - |
| Effect of forex changes on cash | 141.7 Million | - | - | - | -600 Thousand | - |
| Net cash flow / Change in cash | 18.79 Billion | -61.35 Billion | 7.57 Billion | -38.28 Billion | 2.29 Billion | 5.06 Billion |
| Free Cash Flow | -10.96 Billion | 9.36 Billion | 7.57 Billion | 5.7 Billion | -3.33 Billion | 5.06 Billion |
3075
9385
8030
JASH
4320
PRIMESECU